Catalyst Wire Dossier Catalyst Wire Dossier

CKD-314 (Nafabelltan)

Nafabelltan · Chong Kun Dang Pharmaceutical
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CKD-314 (Nafabelltan), covering 2021-02-02 to 2021-02-02. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia [Phase 2]

See pricing